Immunogenicity, safety, and tolerability of the meningococcal serogroup B bivalent rLP2086 vaccine in adult laboratory workers.
BACKGROUND
The bivalent rLP2086 vaccine is approved in the United States to prevent meningococcal disease caused by Neisseria meningitidis serogroup B (MnB) in individuals aged 10-25 years. The immunogenicity and safety of bivalent rLP2086 were evaluated in microbiologists 24-62 years old who handle MnB.


METHODS
Seven subjects vaccinated at 0, 2, and 6 months had functional antibodies measured before vaccination and 1 month after each dose by serum bactericidal assays using human complement (hSBAs) and 4 vaccine-heterologous MnB test strains.


RESULTS
Six subjects qualified for analysis. All demonstrated hSBA titers ≥the lower limit of quantitation (LLOQ) against 3 of 4 strains; 3 subjects achieved titers ≥LLOQ for the fourth. Safety-related events following vaccination were generally mild to moderate in severity.


CONCLUSIONS
Three doses of bivalent rLP2086 were generally well tolerated in laboratory personnel and elicited protective functional immune responses reflective of broad coverage against MnB disease.
['Reiner|David M|DM|', 'Bhuyan|Prakash|P|', 'Eiden|Joseph J|JJ|', 'Ginis|John|J|', 'Harris|Shannon|S|', 'Jansen|Kathrin U|KU|', 'Jiang|Qin|Q|', 'Jones|Thomas R|TR|', "O'Neill|Robert E|RE|", 'York|Laura J|LJ|', 'Perez|John L|JL|']
D000328:Adult D000907:Antibodies, Bacterial D005260:Female D006801:Humans D007115:Immunization Schedule D059232:Laboratory Personnel D008297:Male D008589:Meningococcal Infections D022401:Meningococcal Vaccines D008875:Middle Aged D038541:Neisseria meningitidis, Serogroup B D012449:Safety D015610:Serum Bactericidal Test
Serogroup B Bivalent rLP2086 Vaccine Laboratory worker Meningococcal disease Neisseria meningitidis